The present invention relates to the administration of levosimendan during liver cirrhosis: the administration of levosimendan reduces the formation of fibrotic nodules in the liver and thus the concentration of bilirubin in blood. The administration of levosimendan reduces the suffering of liver wherein cirrhosis was induced and this is demonstrated by the reduced levels of AST and ALT. Levosimendan improves the metabolism and thus the brain functionality during liver cirrhosis.
